Impact of nivolumab on persistence of functional TAA-T cells. (A) Comparison of T-cell reactivity to the targeted antigens as detected by IFNγ ELISPOT assay after nivolumab priming and before TAA-T infusion and at 3 months between responding (R) and nonresponding patients (NR). (B) Persistence of polyfunctional TAA-T cells over time in responders. (C) Persistence of polyfunctional TAA-T cells over time in nonresponders. (D) Representative plot of patient demonstrating recovery of in vivo polyfunctional CD4⁺ and CD8⁺ TAA-T cells secreting both IFNγ and TNFα was detected after brief ex vivo expansion after restimulation with antigens at several follow-up time points.